Skip to content
News5 min readStandard

Psychiatry Panel Weighs Ketamine Data Against Psychedelic Hype

A psychiatry panel compares ketamine's dosing model to newer oral antidepressants and warns that enthusiasm for psychedelics is outpacing the evidence.

Ketamine Resource Editorial Team··Reviewed by Ketamine Resource Editorial Review
Psychiatry Panel Weighs Ketamine Data Against Psychedelic Hype article visual for Ketamine Resource

Editorial review

Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.

A Psychiatry Panel Questions Whether Psychedelic Hype Has Outrun the Data

A video panel discussion published by Psychiatric Times on November 18, 2026 brings together three clinicians, Erin Crown, MHS, PA-C; Leslie L. Citrome, MD, MPH; and Lisa Harding, MD, to compare rapid-acting depression treatments, including ketamine, esketamine, a newer oral combination, and psychedelics. The segment is framed as opinion and discussion rather than original research, and this article draws only on that Psychiatric Times report, so the claims below reflect what the panelists stated on camera rather than independent corroboration.

The panel's throughline is that "rapid-acting" no longer describes one category of treatment. Dr. Citrome introduced the oral combination of dextromethorphan and bupropion as an accessible, ketamine-like option, something a patient could take as a daily pill rather than attend an infusion or nasal spray appointment for. Dr. Harding pushed back on equating the two, explaining that dextromethorphan works as an NMDA receptor antagonist, the same broad mechanism class as ketamine, while bupropion's role in the combination is mostly to slow the enzyme that would otherwise break dextromethorphan down quickly, rather than to act through its usual antidepressant pathway.

Daily Pills Versus Pulsatile Dosing: Why the Distinction Matters

According to the panel discussion, Dr. Harding drew a specific contrast between dosing models. The oral dextromethorphan-bupropion combination is taken daily, while ketamine and esketamine are typically delivered twice weekly for four weeks in a pulsatile pattern, with therapeutic effects reported to persist after the drug itself has cleared the body. That distinction matters for patients weighing options: a pulsatile, supervised dosing schedule is a different commitment and a different safety model than a once-daily tablet, even when both target the same NMDA receptor system.

Dr. Harding also noted, per the panel, that the STRIDE trial did not meet its efficacy endpoint for the dextromethorphan-bupropion combination in treatment-resistant depression, and that solid first-line evidence for ketamine in unipolar depression remains limited. Her point, as reported in the discussion, was that these gaps make direct, apples-to-apples comparisons across rapid-acting compounds difficult right now, not that any one option is proven superior. Dr. Citrome added that dextromethorphan also acts on the sigma-1 receptor, a mechanism he said the field is still working to understand.

Despite those caveats, the panelists agreed that rapid-acting agents have shifted clinical expectations. Dr. Harding pointed to trials, including a newer Alzheimer's agitation indication she referenced, showing separation from placebo within one to two weeks, which she said has changed how she counsels patients on what to expect from treatment timelines.

Compare evidence and options

Compare ketamine with other treatment paths using neutral explainers.

Compare options

Key Takeaway

Per the panel reported by Psychiatric Times, more than 60 percent of clinician respondents in an educational poll Dr. Harding cited incorrectly attributed psychedelics' mechanism of action to NMDA receptor antagonism, the mechanism associated with ketamine rather than classic psychedelics. If that confusion exists among some clinicians, patients researching treatment options should expect to ask providers directly how a given compound is thought to work and what evidence supports that mechanism, rather than assuming all "rapid-acting" or "psychedelic-adjacent" options are interchangeable.

Why the Panel Says Psychedelic Enthusiasm Has Outpaced the Evidence

Dr. Harding, as described in the Psychiatric Times discussion, argued that psychedelics have generated clinical and public enthusiasm ahead of the underlying science. She pointed to off-label ketamine use, emerging at-home compounds sometimes marketed as "neuroplastogens," and the mechanism-confusion poll noted above as evidence of that gap. She also referenced the STAR*D trial's well-documented pattern of declining response rates across successive treatment steps, using it to argue that the field still underestimates how difficult depression treatment can be for patients who have already failed one or more therapies.

The panel raised open questions rather than answers on newer agents: Dr. Harding flagged unresolved redosing criteria and monitoring protocols for emerging compounds, and Dr. Citrome asked whether a therapeutic effect could ever be separated from the subjective psychedelic experience itself, and how much supervised time redosing sessions would realistically require. None of these questions were resolved in the discussion, and the panel did not cite specific studies answering them.

What This Means For Readers Comparing Ketamine Providers

For readers evaluating ketamine therapy against newer oral or psychedelic-adjacent options, a few practical distinctions from this panel discussion are worth carrying into conversations with a provider. First, ketamine and esketamine's twice-weekly, supervised dosing model is structurally different from a daily pill, and that difference affects cost, time commitment, and the level of clinical monitoring involved, independent of which option ends up working better for a given patient. Second, the panel's point about limited first-line ketamine data in unipolar depression is a reminder that most ketamine evidence to date concerns treatment-resistant cases, so patients considering it as an early-line option should ask their provider how the evidence base applies to their specific diagnosis and treatment history. Third, given the mechanism confusion the panel described among some clinicians, it is reasonable for patients to ask a prospective provider to explain, in plain terms, what receptor system a proposed treatment targets and what that does and does not predict about outcomes. This article summarizes one panel's clinical opinions as reported by Psychiatric Times; it is not a review of new trial data, and readers should treat the mechanistic and efficacy claims above as the panelists' stated views rather than independently verified findings.

Share

Contact Ketamine Resource

Send corrections, partnership questions, or advertising inquiries.

Contact the site